Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director
Infex Therapeutics is pleased to announce the appointment of Professor Colm Leonard as a Non-Executive Director of Infex with immediate…
Antimicrobial discovery and drug development – RSC Podcast
How do we develop drugs like antibiotics? How long does it take for such a drug to go from its inception in a research lab to use in a…
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
This designation gives MET-X an accelerated U.S. regulatory pathway and an additional five-years of market exclusivity upon approval.
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the first subjects have been dosed in Phase I study in…
Infex Awarded Biomedical Catalyst Grant For COV-X Project
Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a successful grant award of £850,000 to support its 18…
COVID-19 Pandemic Triggers Upsurge in MBL Infections
New research has discovered that the ongoing COVID-19 pandemic has triggered a significant upsurge in metallo-β-lactamase (MBL)……
CARB-X Receives Additional $370m from U.S. Government and Wellcome
Enables continued investment in innovative projects to tackle the growing global threat posed by AMR
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022
Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism
Infex Therapeutics, one of the UK’s leading infectious disease biotech companies, has today lauded the conclusions of a NHS England and the…
Infex scientists achieve breakthrough to overcome critical priority drug resistant infections
One of the UK’s leading infectious disease biotech companies has announced a breakthrough in an antimicrobial resistance (AMR) program that…